BioXcel Therapeutics
BTAI
43 hedge funds and large institutions have $63.3M invested in BioXcel Therapeutics in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 7 reducing their positions, and 10 closing their positions.
157% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 7
115% more capital invested
Capital invested by funds: $29.4M → $63.3M (+$33.9M)
0.16% less ownership
Funds ownership: 1.66% → 1.5% (-0.16%)
2% less funds holding
Funds holding: 44 → 43 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$578K |
| 2 |
DAM
DLD Asset Management
New York
|
+$411K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$283K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$165K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$121K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.12M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$898K |
| 3 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
-$733K |
| 4 |
Squarepoint
New York
|
-$78.1K |
| 5 |
RA
Rational Advisors
Huntington,
New York
|
-$48K |
BTAI Hedge Fund Activity: Q4 2019 in Review
43 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q4 2019, worth a combined $63.3M — up 115% from $29.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of BTAI and 9 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 18 added.
The largest buyer was BlackRock, adding an estimated $578K. The largest seller was CVI Holdings, exiting entirely with an estimated $1.12M sold.
- 43 institutional investors held BioXcel Therapeutics (BTAI) as of Q4 2019, down from 44 in Q3 2019.
- Funds reported $63.3M of BioXcel Therapeutics stock for Q4 2019, up 115% quarter-over-quarter.
- 9 funds opened new BioXcel Therapeutics positions in Q4 2019 and 10 closed out, a net change of -1 holder.
- The largest BioXcel Therapeutics buyer in Q4 2019 was BlackRock, an estimated $578K added.
- The largest BioXcel Therapeutics seller in Q4 2019 was CVI Holdings, an estimated $1.12M sold.
Based on aggregated 13F filings for Q4 2019.